Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Chief Medical Officer | February 13, 2025 | February 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date February 13, 2025 · Filed February 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.81 · Expires 2035-02-12 | Direct | 174,960 |
Reported balance
After 2025-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-13 · Grant · Acquired 174,960 · Balance 174,960 F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 14, 2025 16:07 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 174,960 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001842952-25-000020 · wk-form4_1739567246.xml · derivative · entry 1 Dansky Ullmann Claudio · CIK 0002030789 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,960 Underlying: Common Stock · 174,960 shares Expires 2035-02-12 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 13, 2026, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 17:18 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 202,170 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001842952-24-000062 · wk-form4_1722547103.xml · derivative · entry 1 Dansky Ullmann Claudio · CIK 0002030789 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,170 Underlying: Common Stock · 202,170 shares Expires 2034-07-31 F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on August 1, 2025, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.